Back to Journals » Clinical Ophthalmology » Volume 5

Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

Authors He L, Chan, Leng T , Blumenkranz MS

Published 9 December 2011 Volume 2011:5 Pages 1751—1758

DOI https://doi.org/10.2147/OPTH.S26631

Review by Single anonymous peer review

Peer reviewer comments 2



Lingmin He, Annie Chan, Theodore Leng, Mark S Blumenkranz
Department of Ophthalmology, Stanford University School of Medicine, Stanford, California, USA

Background: The purpose of this study was to characterize central macular thickness and retinal volume following intravitreal injections using time domain and spectral domain optical coherence tomography (TD-OCT and SD-OCT, respectively).
Methods: Nine patients with macular edema secondary to diabetes or retinal vein occlusion treated with intravitreal triamcinolone 4.0 mg and/or bevacizumab 1.25 mg were enrolled. Central macular thickness and volume was measured by SD-OCT and TD-OCT scan at baseline, and 1, 3, 6, 24, 48 hours, and 1 week postinjection.
Results: Equations were derived to describe central macular thickness and volume reduction in the hours following intravitreal injection. Measurements of central macular thickness by SD-OCT were significantly reduced by 3 hours (P = 0.03) and retinal volume by 6 hours (P = 0.03). Central macular thickness measured 40.9 (28.6–53.2) µm thicker on the SD-OCT instrument while volume measured 3.47 (3.27–3.66) mm3 higher.
Conclusion: Significant central macular thickness and volume reductions occur in the first hours after injection with triamcinolone and/or bevacizumab.

Keywords: retinal vein occlusion, intravitreal injection, diabetic retinopathy

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.